Quick Answer
Atea Pharmaceuticals, Inc. reported Total Assets of $315.22 million for the year ending 2025.
- Atea Pharmaceuticals, Inc. showed a decrease of -32.2% in Total Assets from 2024 to 2025.
- This data is from Atea Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $110.11 million | Q1 2021: $840.65 million | Q2 2021: $871.54 million | Q3 2021: $843.50 million | Q1 2022: $717.19 million | Q2 2022: $694.34 million | Q3 2022: $686.58 million | Q1 2023: $638.13 million | Q2 2023: $626.03 million | Q3 2023: $608.08 million | Q1 2024: $553.03 million | Q2 2024: $510.38 million | Q3 2024: $490.96 million | Q1 2025: $439.96 million | Q2 2025: $391.61 million | Q3 2025: $342.96 million.
- Over the full 7 years of available data (2019 to 2025), Atea Pharmaceuticals, Inc.'s Total Assets has grown by 1,328.1%.
- Historical annual values: Fiscal year 2025: $315.22 million | Fiscal year 2024: $464.67 million | Fiscal year 2023: $594.97 million | Fiscal year 2022: $666.71 million | Fiscal year 2021: $772.89 million | Fiscal year 2020: $863.63 million | Fiscal year 2019: $22.07 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: